Short Interest in Inogen, Inc. (NASDAQ:INGN) Expands By 6.7%

Inogen, Inc. (NASDAQ:INGN) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 794,700 shares, a growth of 6.7% from the November 15th total of 744,800 shares. Based on an average daily trading volume, of 192,900 shares, the days-to-cover ratio is presently 4.1 days.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on INGN shares. StockNews.com upgraded Inogen from a “hold” rating to a “buy” rating in a research report on Thursday, December 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Friday, November 8th.

Inogen Stock Performance

Shares of NASDAQ:INGN opened at $8.95 on Tuesday. Inogen has a 1 year low of $5.08 and a 1 year high of $13.33. The stock has a 50-day simple moving average of $9.50 and a 200-day simple moving average of $9.73. The stock has a market capitalization of $213.17 million, a P/E ratio of -3.98 and a beta of 1.02.

Institutional Investors Weigh In On Inogen

Several large investors have recently made changes to their positions in INGN. Price T Rowe Associates Inc. MD boosted its position in Inogen by 5.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company’s stock worth $193,000 after purchasing an additional 1,188 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Inogen during the second quarter worth about $30,000. BNP Paribas Financial Markets boosted its position in shares of Inogen by 13.9% in the third quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after buying an additional 5,131 shares during the period. Geode Capital Management LLC grew its stake in shares of Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after buying an additional 5,921 shares in the last quarter. Finally, Quarry LP acquired a new stake in Inogen in the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.